A Pharmacokinetics and Safety Study of Augmentin ES-600 in Children With CAP and ABRS
An Open Label, Single Arm Study, to Evaluate the Pharmacokinetics and Safety of Augmentin Extra Strength (ES)-600 Suspension in Children Presenting With Community Acquired Pneumonia (CAP) and Acute Bacterial Rhinosinusitis (ABRS) in Brazil
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: US GSK Clinical Trials Call Center
- Phone Number: 877-379-3718
- Email: GSKClinicalSupportHD@gsk.com
Study Contact Backup
- Name: EU GSK Clinical Trials Call Center
- Phone Number: +44 (0) 20 89904466
- Email: GSKClinicalSupportHD@gsk.com
Study Locations
-
-
-
São Paulo, Brazil, 1223001
- GSK Investigational Site
-
-
São Paulo
-
Ribeirão Preto, São Paulo, Brazil, 14051-140
- GSK Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- The participant and/or parent(s)/legal guardian(s) are willing and able to comply with the study protocol.
- In accordance with regional/local laws and regulations,
- a. the parent(s)/legal guardian(s) has given signed informed, dated consent; and the participant has
- b.given written assent, if applicable, to participate in the study (for participants between 7 to 12 years)
- Age: Participant must be aged greater than or equal to (>=) 3 months to 12 years, of either gender.
- Participants who are otherwise healthy and presenting with suspected CAP.
- For participants clinically suspected of CAP, at least 3 of the following 4 criteria are applicable:
- a) History of productive cough and/or shortness of breath.
- b)Fever greater than (>)38.5 degree Celsius (○C) (Axillary temperature)
- c) Tachypnea as defined by Respiratory rate (RR) >= 50 breaths/minute in children up to 11 months RR >= 40 breaths/minute in children from 12 months onwards
- d) Chest X-Ray with shadow or lobar condensation, unilateral or bilateral.
For participants of ABRS:
- The participant and/or parent(s)/legal guardian(s) are willing and able to comply with the study protocol.
- In accordance with regional/local laws and regulations,
- a..The parent(s)/legal guardian(s) has given signed informed, dated consent; and the participant has
- b. given written assent, if applicable, to participate in the study (for participants between 7 to 12 years).
- Age: Participant must be between >=3 months to 12 years of either gender.
- Participants who are otherwise healthy and presenting with suspected ABRS.
- For participants of clinically suspected ABRS, the participants would be eligible if any of the following 2 of the 3 criteria stated below are met:
- a.Children with purulent nasal discharge or daytime productive cough (which may worsen at night) or both persisting for 10 days or more without evidence of improvement.
- b. Fever > 38.3○C (Axillary temperature)
- c. Double sickness defined as initial improvement of symptoms and further worsening/ deterioration after 5 days.
Exclusion Criteria:
- Severe ABRS/CAP requiring hospitalization.
- Currently receiving or has received more than one dose of systemic antibiotic therapy within one week prior to the initiation of the study.
- A serious underlying disease as per clinician's judgment.
- Human immunodeficiency virus (HIV) infection/or any other immunosuppressive condition
- Pre-existing renal insufficiency (for example [e.g.], plasma creatinine > 1.5 times upper limit of normal range for age).
- Pre-existing liver disease(s) and/or hepatic dysfunction.
- Any pre-existing malignancy/any participants undergoing any kind of chemotherapy.
- Evidence of leukopenia and/or thrombocytopenia.
- History of previous hypersensitivity reaction to penicillins, cephalosporins or other Beta-lactam antibiotics.
- History of amoxicillin-clavulanate associated cholestatic jaundice/hepatic dysfunction.
- History of phenylketonuria or a known hypersensitivity to aspartame.
- Received, within 48 hours of study entry, or is scheduled to receive during the study period, any medication which may alter bowel function.
- Received, within 48 hours of study entry, or is scheduled to receive during the study period, any medication which may alter renal function like probenecid.
- Participants who have chronic sinusitis (signs and symptoms lasting greater than 28 days prior to screening visit.
- Significant abnormalities of the sinuses and any complications of ABRS.
- Have concurrent streptococcal pharyngitis or acute otitis media (as the standard doses for both of these conditions is 10 days).
- Any other infection or condition, which necessitates use of a concomitant systemic antimicrobial.
- History of infectious mononucleosis.
- History of pseudomembranous colitis.
- Participants that are on warfarin therapy.
- Receipt of an investigational compound (non-food and drug administration [FDA] and non-Brazil National Health Surveillance Agency [ANVISA] approved) or device within the previous 30 days or five half-lives, whichever is longer, preceding the first dose of study intervention or during the study.
- Participants with symptoms suggestive of active Coronavirus disease 2019 (COVID-19) infection (that is (i.e.), fever, cough, etc.)
- Participants with known COVID-19 positive contacts within the past 14 days.
- Female participants who have attained menarche
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Participants with CAP and ABRS
|
Amoxicillin and clavulanic acid in fixed dose combination will be administered
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Absorption rate constant (Ka) of amoxicillin and clavulanic acid combination
Time Frame: Up to 10 days
|
Up to 10 days
|
|
Area under the serum concentration-time curve (AUC) of amoxicillin and clavulanic acid combination
Time Frame: Up to 10 days
|
Up to 10 days
|
|
Maximum serum concentration (Cmax) of amoxicillin and clavulanic acid combination
Time Frame: Up to 10 days
|
Up to 10 days
|
|
Clearance (CL) of amoxicillin and clavulanic acid combination
Time Frame: Up to 10 days
|
Up to 10 days
|
|
Volume of distribution (Vd) of amoxicillin and clavulanic acid combination
Time Frame: Up to 10 days
|
Up to 10 days
|
|
Terminal half-life (t1/2) of amoxicillin and clavulanic acid combination
Time Frame: Up to 10 days
|
Up to 10 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Number of participants with treatment emergent adverse events (TEAE)
Time Frame: Up to Day 14
|
Up to Day 14
|
|
Number of participants achieving Primary Clinical Response
Time Frame: Day 11 to Day 14
|
Day 11 to Day 14
|
|
Number of participants achieving Secondary Clinical response
Time Frame: Day 22 to Day 28
|
Day 22 to Day 28
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: GSK Clinical Trials, GlaxoSmithKline
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 215335
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.